Company intelligence / Profile preview

Vayodaanta

Cambridge, Massachusetts, United Statesdnb.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Lead candidate VE303 showed positive Phase 2 results for prevention of recurrent C. difficile infection; Phase 3 pivotal trial (RESTORATiVE303) is currently underway with topline data expected in 2026. VE202 is in Phase 2 for ulcerative colitis.

Therapeutic areas: GastroenterologyOncologyImmunologyInfectious Diseases
Modalities: Live Biotherapeutic Products (LBP)defined bacterial consortia
Industry: Biotech

Drug pipeline

3 assets

Poly-herbal formulation with synbiotics

Pre-clinical

Indications: Rheumatoid arthritis

2 more assets in the full pipeline.

Request access →

Partnerships

Bristol Myers SquibbPfizerBARDA (Biomedical Advanced Research and Development Authority)

Beyond the preview

Go deeper on Vayodaanta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vayodaanta.

Explore the full profile